Taiwan’s listed biotech company, Royal Target, is facing increased scrutiny following disputes surrounding its recent board of directors election. Regulators are questioning the process and demanding detailed explanations, citing inconsistencies and a lack of clarity in the reported proceedings. Concerns center on evolving narratives regarding the election details, prompting officials to repeatedly request specific procedural information. The company’s handling of the election has drawn criticism, fueling uncertainty among investors. Authorities are focused on ensuring the election adhered to legal and regulatory standards. The ongoing investigation aims to determine if any irregularities occurred during the board member selection. Further details are expected as the regulatory review continues.